Conclusions
GLS did not predict long-term outcome in patients presenting to the ED
with chest pain and suspected ACS with neither a diagnostic ECG or
elevated cardiac enzymes. These data support our findings in the
original 2DSPER multicenter study, and together with the SUCCOUR study,
emphasize the need for large prospective trials to evaluate the clinical
utility of GLS. We conclude that 2DLS is not a useful tool for the
diagnosis of ACS and for predicting outcome in low to intermediate risk
patients presenting to the ED with chest pain and suspected ACS.
Conflict of interest: NLC, DSB, SS, MJ, ML and AS report
non-financial support from GE Healthcare, Haifa, Israel, during the
conduct of the study.